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Background: This study aimed to assess the combined performance of serum (1,3)-β-D-glucan (BDG) and
procalcitonin (PCT) for the differential diagnosis between candidaemia and bacteraemia in three intensive
care units (ICUs) in two large teaching hospitals in Italy.
Methods: From June 2014 to December 2015, all adult patients admitted to the ICU who had a culture-
proven candidaemia or bacteraemia, as well as BDG and PCT measured closely to the time of the index
culture, were included in the study. The diagnostic performance of BDG and PCT, used either separately
or in combination, was assessed by calculating the sensitivity, specificity, positive predictive value (PPV),
negative predictive value (NPV), and positive and negative likelihood ratios (LR+ and LR–). Changes from
pre-test probabilities to post-test probabilities of candidaemia and bacteraemia were inferred from Fagan’s
nomograms.
Results: One hundred and sixty-six patients were included, 73 with candidaemia (44%) and 93 with bacteraemia
(56%). When both markers indicated candidaemia (BDG ≥80 pg/ml and PCT <2 ng/ml) they showed higher PPV
(96%) compared to 79% and 66% for BDG or PCT alone, respectively. When both markers indicated bacteraemia
(BDG <80 pg/ml and PCT ≥2 ng/ml), their NPV for candidaemia was similar to that of BDG used alone (95% vs. 93%).
Discordant BDG and PCT results (i.e. one indicating candidaemia and the other bacteraemia) only slightly altered the
pre-test probabilities of the two diseases.
Conclusions: The combined use of PCT and BDG could be helpful in the diagnostic workflow for critically ill patients
with suspected candidaemia.
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Differentiating candidaemia from bacteraemia is a tough
diagnostic challenge for clinicians worldwide, mainly be-
cause of their very similar clinical presentation [1–4].
Although blood cultures remain the mainstay for a def-
inite aetiological diagnosis, their low sensitivity and slow
turn-around time have prompted the development of
rapid antigen-based diagnostic methods, such as the
(1,3)-β-D-glucan (BDG) assay, as useful tools for antici-
pating the diagnosis of candidaemia and especially for
excluding it, strengthening the diagnosis of bacteraemia
and favouring the safe discontinuation of useless anti-
fungal treatments [5–8].
In addition to serum fungal antigens, other less spe-
cific markers might help clinicians in the differential
diagnosis between candidaemia and bacteraemia. For ex-
ample, serum procalcitonin (PCT), a well-recognized
marker of bacteraemia, has been suggested to be normal
or only slightly increased in candidaemia [9–13]. How-
ever, a still unanswered question is how to interpret and
balance the results of PCT and BDG when used in com-
bination for the differential diagnosis between the two
diseases.
The primary objective of this study was to assess the
combined performance of PCT and BDG for the differ-
ential diagnosis between candidaemia and bacteraemia
in critically ill patients in the intensive care unit (ICU).
Methods
This multicentre retrospective study was conducted in
three adult ICU wards of two large Italian tertiary care
centres; two in Ospedale Policlinico San Martino, a
1200-bed teaching hospital in Genoa, and one in Policli-
nico Agostino Gemelli, a 1400-bed teaching hospital in
Rome. In both hospitals, BDG testing is routinely used
for diagnostic purposes in patients with signs and symp-
toms of infection and considered at risk of candidaemia
according to clinical judgement.
From June 2014 to December 2015, all critically ill pa-
tients with candidaemia or bacteraemia fulfilling the fol-
lowing criteria were included in the study: 1) 18 years of
age or older; 2) BDG testing performed within 48 h be-
fore or after the time of the index culture; and 3) serum
PCT measured within 24 h before or after the time of
the index culture. The different window of time for BDG
and PCT was arbitrarily selected in view of the different
kinetics in the blood of the two markers with respect to
the infectious syndrome [14, 15]. The time of the index
culture was defined as the day on which the first blood
culture, which later resulted positive for Candida spp. or
bacteria, was drawn. Patients with mixed infections (de-
fined as presence of positive cultures for Candida spp.
and bacteria less than 48 h apart) were excluded from
the study.Definitions of candidaemia and bacteraemia
Candidaemia and bacteraemia were defined as the pres-
ence of at least one blood culture positive for Candida
or bacteria, respectively, in presence of signs and symp-
toms of infection [16, 17]. For coagulase-negative
staphylococci and other common skin contaminants, at
least two consecutive blood cultures positive for the
same pathogen were deemed necessary to define bacter-
aemia [18].Data collected for the analysis
The following demographic and clinical characteristics
were retrieved from medical records and laboratory da-
tabases at the time of candidaemia or bacteraemia: age,
gender, type of patient (surgical vs. medical), previous
abdominal surgery (within 30 days), chronic renal fail-
ure, diabetes mellitus, Charlson comorbidity score [19],
presence of a central venous catheter (CVC) from more
than 48 h, haemodialysis, receipt of corticosteroids, re-
ceipt of albumin, receipt of immunoglobulins, previous
antibiotic therapy (within 30 days), previous antifungal
therapy (within 30 days), Candida colonization (defined
as one or more Candida-positive cultures from non-
sterile sites), and length of hospital stay prior to the
onset of candidaemia or bacteraemia.Laboratory
BDG evaluation was performed with the Fungitell assay
(Associates of Cape Cod, Cape Cod, MA, USA). BDG
samples were stored at –20 °C, and assays were per-
formed according to the manufacturer’s recommenda-
tions. Values lower than 80 pg/ml and higher than
500 pg/ml were reported as <80 pg/ml and >500 pg/ml,
respectively.
Procalcitonin (PCT) was measured by a quantitative
sandwich chemiluminescence immunoassay (CLIA; Li-
aison® BRAHMS® PCT II GEN, DiaSorin, Saluggia, Italy)
optimized on an automated analytical platform (Liaison®
XL, DiaSorin, Saluggia, Italy) [20]. The method is based
on a specific monoclonal antibody coated on the mag-
netic particles; a second antibody is linked to an
isoluminol-conjugate antibody. After the first incubation,
the solid phase is added to the reaction and in the pres-
ence of PCT a sandwich is formed. The intra- and inter-
assay imprecision, expressed as coefficient of variation
(CV, %) ranged 1.0–4.8% and 3.5–16.4%, respectively,
depending on the PCT concentration.
Identification of bacteria and Candida spp. was per-
formed by the VITEK 2 automated system (bioMérieux,
Marcy l’Etoile, France) or by MALDI-TOF mass spec-
trometry (Bruker Daltonik, Bremen, Germany), in ac-
cordance with the laboratory diagnostic procedure
adopted in Genoa and in Rome, respectively.
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Categorical variables are presented as absolute fre-
quencies and percentages, while continuous variables
are presented as median value and interquartile range
(IQR).
The collected demographic and clinical characteristics
of patients were tested for their association with candi-
daemia or bacteraemia by univariable analysis, by means
of the chi-square test, the Fisher exact test, or the
Mann-Whitney U test, as appropriate.
The diagnostic performance of BDG and PCT used
separately for differentiating between the two diseases
was assessed by calculating their sensitivity, specificity,
positive predictive value (PPV), negative predictive value
(NPV), positive likelihood ratio (LR+), and negative like-
lihood ratio (LR–) for the diagnosis of candidaemia over
bacteraemia in our population, at different cut-off levels.
Among the explored thresholds, we also included the
standard BDG and PCT thresholds (80 pg/ml and
0.5 ng/ml) reported in the literature for the diagnosis of
candidaemia per se and bacteraemia per se, respectively
[9, 21]. The optimal BDG and PCT cut-offs in our popu-
lation were defined as the points with the maximum
Youden Index on the respective receiver-operating char-
acteristic (ROC) curves.Fig. 1 Flow chart of the patient inclusion process. BDG (1,3)-β-D-glucan, PCTo verify that both BDG and PCT were independently
associated with the diagnosis of candidaemia over bacter-
aemia, their serum values were dichotomised according to
their optimal cut-offs, and included in a multivariable
stepwise backward logistic regression along with demo-
graphic and clinical factors showing an association with
candidaemia in univariable comparisons (p < 0.10). Subse-
quently, their combined performance for the diagnosis of
candidaemia over bacteraemia was reported in terms of
sensitivity, specificity, PPV, NPV, LR+, and LR–.
Finally, changes from the pre-test probability (approxi-
mating to the prevalence of disease by assuming a simi-
lar individual risk among tested patients) to the post-test
probability of candidaemia and bacteraemia (the latter
defined as 1 – probability of candidaemia) were inferred
from Fagan’s nomograms [22] for either BDG and PCT
used alone or in combination.
The analyses were performed using SPSS Statistics ver-
sion 21.0 (IBM Corp., Armonk, NY, USA) and R Statis-
tical Software version 3.3.0 (R Foundation for Statistical
Computing, Vienna, Austria).
Results
During the study period, 166 patients were included in
the study (Fig. 1). Of these, 73 had candidaemia and 93T procalcitonin
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complete demographic and clinical characteristics of
the patients, as well as their possible association with
candidaemia or bacteraemia in univariable analysis,
are reported in Table 1. Patients with candidaemia
were more likely than those with bacteraemia to have
a CVC (82% vs. 65%), have been treated with antibi-
otics (88% vs. 49%), and have a longer hospital stay
before the development of the defining infection (me-
dian 21 vs. 14 days). The other baseline characteris-
tics were not significantly different between the two
populations.
The distribution of BDG and PCT values in patients
with bacteraemia and candidaemia is shown in Fig. 2.Table 1 Demographic and clinical characteristics of patients
with candidaemia and bacteraemia at the time of infection
Variable Candidaemia*
(n = 73, 44%)
Bacteraemia**
(n = 93, 56%)
P
Demographic variables
Age, years (median (IQR)) 64 (52–76) 67 (48–73) 0.439
Male gender 43 (59) 54 (58) 0.913
Clinical variables
Type of patient 0.502
Surgical 28 (38) 31 (33)
Medical 45 (62) 62 (67)
Previous abdominal surgery 13 (18) 16 (17) 0.919
Chronic renal failure 19 (26) 23 (25) 0.849
Diabetes mellitus 14 (19) 20 (22) 0.712
Charlson score (median (IQR)) 3 (2-4) 2 (2-5) 0.546
Presence of CVC 60 (82) 60 (65) 0.012
Haemodialysis 7 (10) 13 (14) 0.389
Receipt of albumin 6 (8) 17 (18) 0.073
Receipt of immunoglobulins 0 (0) 2 (2) 0.504
Corticosteroid therapy 15 (21) 17 (18) 0.713
Previous antibiotics 64 (88) 46 (49) <0.001
Previous antifungals 12 (16) 8 (9) 0.124
Candida colonization 21 (29) 23 (25) 0.599
Time from admission to
candidaemia or bacteraemia,
days (median (IQR))
21 (10–46) 14 (8–29) <0.001
Values are shown as n (%) unless otherwise indicated
* Candida albicans (n = 37), Candida parapsilosis (n = 23), Candida tropicalis
(n = 7), Candida glabrata (n = 4), Candida guilliermondii (n = 1), Candida
lusitaniae (n = 1)
** Klebsiella spp. (n = 23), Staphylococcus aureus (n = 12), Escherichia coli
(n = 11), Pseudomonas aeruginosa (n = 11), coagulase-negative staphylococci
(n = 8), Enterococcus spp. (n =5), Enterobacter spp. (n = 4), Proteus spp. (n = 4),
Serratia spp. (n = 3), Acinetobacter spp. (n = 2), Streptococcus spp. (n = 2),
Citrobacter spp. (n = 1), Providencia spp. (n = 1), Pseudomonas aeruginosa +
Staphylococcus aureus (n = 1), Acinetobacter spp. + Pseudomonas aeruginosa
(n = 1), Acinetobacter spp. + Staphylococcus aureus (n = 1), Enterococcus spp.
+ Klebsiella spp. (n = 1), Escherichia coli + Klebsiella spp. (n = 1), Escherichia
coli + Pseudomonas aeruginosa (n = 1)
CVC central venous catheter, IQR interquartile rangeMost patients were tested for BDG (139/166, 84%) and
PCT (143/166, 86%) within 12 h before and 24 h after
the positive blood draw. Patients with candidaemia had
higher BDG values (median >500 vs. <80 pg/ml, p <
0.001) and lower PCT values (median 0.76 vs. 4.32 ng/
ml, p < 0.001) than those with bacteraemia. The optimal
discriminatory cut-offs of BDG and PCT for diagnosing
candidaemia over bacteraemia in our population were
BDG ≥113 pg/ml and PCT <1.93 ng/ml, respectively
(Fig. 3). As shown in Table 2, the performance of the op-
timal BDG cut-off of ≥113 pg/ml (89% sensitivity, 84%
specificity, 81% PPV, 91% NPV) was very similar to that
of the standard BDG cut-off of ≥80 pg/ml (92% sensitiv-
ity, 81% specificity, 79% PPV, 93% NPV), whereas the
optimal PCT cut-off of <1.93 ng/ml (84% sensitivity, 69%
specificity, 68% PPV, 84% NPV) performed better in
terms of sensitivity and specificity for differentiating be-
tween the two diseases than a PCT cut-off of <0.5 ng/ml
(41% sensitivity, 86% specificity, 70% PPV, 65% NPV).
Although with the limits of subgroup analyses and
without detecting a statistically significant difference,
it is of note that BDG specificity was apparently
lower in patients with Candida colonization than in
those without (78% vs. 86%, p = 0.514), whereas its
sensitivity was similar in those who received antifun-
gals previously and in those who did not (92%% vs
89%%, p = 1). In the multivariable analysis of factors
associated with the diagnosis of candidaemia over
bacteraemia, BDG ≥113 pg/ml (odds ratio (OR) 31.0,
95% confidence interval (CI) 11.0–87.7; p < 0.001) and
PCT <1.93 ng/ml (OR 9.5, 95% CI 3.3–27.1; p <
0.001) were the only two variables independently as-
sociated with the diagnosis.
We then assessed the diagnostic performance of BDG
and PCT used in combination for the diagnosis of candi-
daemia over bacteraemia in our cohort. For practical
purposes, we tested the combination of the widely used
standard BDG cut-off of ≥80 pg/ml (since its perform-
ance was very similar to that of the optimal cut-off of
≥113 pg/ml) and the optimal PCT cut-off of <1.93 ng/ml
rounded to the nearest ng/ml unit (i.e. <2 ng/ml). Sensi-
tivity, specificity, PPV, NPV, LR+, and LR– of BDG and
PCT used in combination for diagnosing candidaemia
over bacteraemia are summarized in Table 3. As re-
ported in Table 3, and graphically in Fig. 4, when both
markers were indicative of candidaemia (BDG ≥80 pg/
ml and PCT <2 ng/ml) they showed a higher PPV for
candidaemia (96%) compared to 79% and 66% when
BDG and PCT were used separately, respectively. In
contrast, when both markers suggested the absence of
candidaemia (i.e. when they were both indicative of bac-
teraemia, BDG <80 pg/ml and PCT ≥2 ng/ml), their
NPV for candidaemia was very similar to that of BDG
used alone (95% vs. 93%, respectively).
Fig. 2 Distribution of BDG and PCT serum levels in patients with bacteraemia or candidaemia. Box plots of the distribution of serum (1,3)-β-D-
glucan (BDG) and procalcitonin (PCT) in study patients, divided according to the type of infection. BDG values lower than 80 pg/ml and higher
than 500 pg/ml were considered as 79 pg/ml and 501 pg/ml, respectively. Outliers for PCT values >30 ng/ml are not displayed in the graph
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Fig. 3 Performance of BDG and PCT for the diagnosis of
candidaemia over bacteraemia in the study population. The area
under the ROC curve was 0.919 for (1,3)-β-D-glucan (BDG) (95% CI
0.875–0.962) and 0.789 for procalcitonin (PCT) (95% CI 0.720–0.856).
The points on the curves with the maximum Youden Index were
113 pg/ml for BDG and 1.93 ng/ml for PCT. Diagnostic performances
of the two markers used alone or combined are detailed in Tables 2
and 3, respectively
Table 2 Sensitivity, specificity, PPV, NPV, LR+, and LR– of BDG and P
bacteraemia in the study population
No./total patients
Cut-off Candidaemia (TP/total) Bacteraemia (TN/total) Sen
BDG
≥80 pg/ml 67/73 75/93 92
≥100 pg/ml 65/73 76/93 89
≥113 pg/ml 65/73 78/93 89
≥120 pg/ml 65/73 78/93 89
≥140 pg/ml 60/73 82/93 82
≥160 pg/ml 60/73 83/93 82
≥180 pg/ml 57/73 85/93 78
≥200 pg/ml 55/73 88/93 75
PCT
<0.50 ng/ml 30/73 80/93 41
<1.00 ng/ml 46/73 75/93 63
<1.93 ng/ml 61/73 64/93 84
<2.00 ng/ml 61/73 62/93 84
<3.00 ng/ml 63/73 54/93 86
<4.00 ng/ml 67/73 49/93 92
<5.00 ng/ml 69/73 43/93 95
BDG (1,3)-β-D-glucan, LR+ positive likelihood ratio, LR– negative likelihood ratio, NPV
true negatives, TP true positives
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BDG and PCT in combination, including the effect of
discordant results (i.e. when one marker indicated candi-
daemia and the other bacteraemia), we used Fagan’s no-
mograms (Additional file 1: Figure S1). Specifically,
Additional file 1 (Figure S1) shows the pre-test and post-
test probabilities of candidaemia according to different
BDG and PCT results (considered both separately and
in combination), at the prevalence of the disease regis-
tered in our study (44%). The pre-test and post-test
probability of bacteraemia can be calculated as 1 minus
the pre-test or post-test probability of candidaemia, re-
spectively. Post-test probabilities of candidaemia and
bacteraemia at prevalences different from that registered
in our study can be inferred manually on Fagan’s nomo-
grams by intersecting the likelihood ratio (LR) of candi-
daemia with a straight line starting from the selected
pre-test probability of the disease (some examples are
provided in Additional file 2, which also propose a pos-
sible therapeutic algorithm to be validated in confirma-
tory studies).
Discussion
In this retrospective study in a cohort of critically ill pa-
tients with candidaemia or bacteraemia, the combined
use of BDG and PCT performed better than the two
markers used separately for identifying true cases ofCT used separately for the diagnosis of candidaemia over
sitivity (%) Specificity (%) PPV (%) NPV (%) LR+ LR–
81 79 93 4.74 0.10
82 79 90 4.87 0.13
84 81 91 5.52 0.13
84 81 91 5.52 0.13
88 85 86 6.95 0.20
89 86 86 7.64 0.20
91 88 84 9.08 0.24
95 92 83 14.01 0.26
86 70 65 2.94 0.68
81 72 74 3.26 0.46
69 68 84 2.68 0.24
67 66 84 2.51 0.25
58 62 84 2.06 0.24
53 60 89 1.94 0.16
46 58 91 1.76 0.12
negative predictive value, PCT procalcitonin, PPV positive predictive value, TN
Table 3 Sensitivity, specificity, PPV, NPV, LR+, and LR– of BDG and PCT used in combination for the diagnosis of candidaemia over
bacteraemia in the study population
No./total patients
Cut-off Candidaemia (TP/total) Bacteraemia (TN/total) Sensitivity (%) Specificity (%) PPV (%) NPV (%) LR+ LR–
BDG ≥80 pg/ml and/or PCT <2 ng/ml 70/73 56/93 96 60 65 95 2.41 0.07
BDG ≥80 pg/ml and PCT <2 ng/ml 48/73 91/93 66 98 96 78 30.58 0.35
BDG (1,3)-β-D-glucan, LR+ positive likelihood ratio, LR– negative likelihood ratio, NPV negative predictive value, PCT procalcitonin, PPV positive predictive value, TN
true negatives, TP true positives
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the disease. Conversely, when both markers indicated
bacteraemia, their performance was similar to that of
BDG used alone, highlighting the high NPV for candi-
daemia of the BDG test.
Recently, Martínez-Jiménez and colleagues [23] re-
ported on the performance of BDG for the diagnosis
of candidaemia in a cohort of 81 patients with either
candidaemia or bacteraemia, showing that the per-
formance of the standard BDG cut-off of ≥80 pg/ml
for diagnosing candidaemia over bacteraemia (84%
sensitivity, 92% specificity, 87% PPV, 90% NPV) was
consistent with that reported in the literature for the
diagnosis of candidaemia per se [5–8, 24–29]. Our re-
sults are in line with these findings, since the overall
performance of the optimal BDG cut-off for the diag-
nosis of candidaemia in our population (≥113 pg/ml)
was very similar to that of the standard cut-off. InFig. 4 Positive predictive value (PPV) and negative predictive value
(NPV) for candidaemia of (1,3)-β-D-glucan (BDG) and procalcitonin
(PCT) considered both separately and in combination. Cut-offs for
candidaemia used for the comparisons in the graph are ≥80 pg/ml
for BDG and <2 ng/ml for PCT. For the combination (BDG+ PCT), the
reported PPV for candidaemia (also readable as NPV for bacteraemia)
was obtained when both markers were concordant in indicating
candidaemia (BDG ≥80 pg/ml and PCT <2 ng/ml), while the
reported NPV for candidaemia (also readable as PPV for bacteraemia)
was obtained when both markers when concordant in indicating
bacteraemia (BDG <80 pg/ml and PCT ≥2 ng/ml)contrast, while a recent meta-analysis showed a PCT
threshold of 0.5 ng/ml to be optimal for the diagnosis
of bacteraemia [9], the same threshold was inadequate
for differentiating bacteraemia from candidaemia in
our study, and a higher value (1.93 ng/ml) performed
far better for this purpose. This result is not surpris-
ing since patients with candidaemia might have
slightly increased PCT values [11–13]. In this regard,
the median PCT concentration of 0.73 ng/ml we
found in patients with candidaemia is in line with
values suggested by other authors for possibly indicat-
ing candidaemia [11–13]. However, it should be noted
that in our population the discriminatory performance
of PCT was overall inferior to that of BDG (sensitiv-
ity 84% and specificity 67% for PCT <2 ng/ml vs.
sensitivity 92% and specificity 81% for BDG ≥80 pg/
ml). For this reason, in our opinion, PCT should be
used cautiously as a single biomarker for diagnosing
or ruling out candidaemia when and where BDG is
not available.
Our following step was to assess the performance of
BDG and PCT used in combination for differentiating
between the two diseases. In this regard, we think three
possibly useful observations stemming from our study
are: 1) in comparison with a positive BDG value consid-
ered alone, the presence of both BDG and PCT indica-
tive of candidaemia might strengthen the clinician’s
confidence in having identified a true episode of the dis-
ease, by increasing specificity and PPV from 81% and
79% to 98% and 96%, respectively; 2) the presence of
both BDG and PCT indicative of bacteraemia does not
particularly add to the already good ability of BDG alone
in ruling out candidaemia, since sensitivity and NPV in-
creased only from 92% and 93% to 96% and 95%, re-
spectively; and 3) in case of discordant BDG and PCT
values, the probabilities of candidaemia and bacteraemia
might be not particularly altered by the results of the
two tests. Given that, in our opinion, the choice on
whether discontinuing antifungals in presence of a nega-
tive BDG plus low PCT values should be taken very cau-
tiously, at least pending cultures results. Indeed, from a
speculative standpoint, we might hypothesise that low
PCT values could help unmask some of the rare false-
negative BDG results, thus preventing from unsafely dis-
continuing antifungals. For example, negative BDG
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candidaemia, as we observed in a previous single-centre
experience also including non-ICU patients and a
higher number of C. parapsilosis isolates [6], albeit
this data has to be confirmed in further, prospective
studies. However, it remains clear that no definite
therapeutic conclusions can be drawn from the
present preliminary two-centre retrospective experi-
ence, and validation is warranted.
The main drawback of our study is its retrospective
nature. Among limitations of the retrospective design is
that blood samples for BDG and PCT testing were not
collected at standardised points in time. Consequently,
some measured values might be different from those
present at the time of the index culture, although this
bias is reduced by the fact that we mainly included pa-
tients who underwent BDG and PCT testing very close
to the positive blood draw. Our aim was indeed to in-
clude only patients at risk of candidaemia who under-
went BDG testing in the presence of signs and
symptoms of the disease and pending cultures results,
therefore reflecting the diagnostic use of the marker in
real life. However, it should also be considered that we
could not always retrospectively explore why clinicians
suspected the disease. Consequently, we cannot be sure
that the high pre-test probability of candidaemia ob-
served in our cohort (44%) reflected only an appropriate
use of BDG or was also dependent on a selection bias,
and thus unrepresentative of the true prevalence of can-
didaemia in patients at risk. Furthermore, although it is
overall reasonable to approximate the pre-test probabil-
ity of a certain disease to its local prevalence in selected
populations, the former is inherently individual and
might increase or decrease because of individual con-
ditions and factors [30]. Sensitivity and specificity of a
marker (and thus the LR of a certain disease) might
also not always be fixed irrespective of prevalence, a
fact that should be considered when extrapolating our
results to other prevalences of candidaemia on Fagan’s
nomograms [31]. Another limitation is that we did
not include mixed infections (candidaemia plus bac-
teraemia). Although their occurrence was uncommon
in our cohort, and thus unlikely to influence the
overall diagnostic performance of the combination,
this might not be the rule in other hospitals and set-
tings [32]. The low rate of mixed infections we de-
tected might also reflect the short window of time we
used for defining an infection as concomitant for
diagnostic purposes. Finally, an important aspect
should be taken into account when interpreting our
results, that is they apply only to critically ill patients
at risk of candidaemia, and cannot be extrapolated to
critically ill patients without risk factors for fungal in-
fections. However, in our opinion restricting theanalysis to patients at risk should be ultimately
viewed more as a strength than a limitation.
Conclusions
The combined use of PCT and BDG could be helpful in
the diagnostic workflow for critically ill patients with
suspected candidaemia. Further studies are needed to
understand whether this might significantly impact
current therapeutic algorithms, as well as be a cost-
effective strategy.
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